Community SARS-CoV-2 seroprevalence before and after the second wave of SARS-CoV-2 infection in Harare, Zimbabwe.

BACKGROUND: By the end of July 2021 Zimbabwe, has reported over 100,000 SARS-CoV-2 infections. The true number of SARS-CoV-2 infections is likely to be much higher. We conducted a seroprevalence survey to estimate the prevalence of past SARS-CoV-2 in three high-density communities in Harare, Zimbabwe before and after the second wave of SARS-CoV-2. METHODS: Between November 2020 and April 2021 we conducted a cross-sectional study of randomly selected households in three high-density communities (Budiriro, Highfield and Mbare) in Harare. Consenting participants answered a questionnaire and a dried blood spot sample was taken. Samples were tested for anti-SARS-CoV-2 nucleocapsid antibodies using the Roche e801 platform. FINDINGS: A total of 2340 individuals participated in the study. SARS-CoV-2 antibody results were available for 70·1% (620/885) and 73·1% (1530/2093) of eligible participants in 2020 and 2021. The median age was 22 (IQR 10-37) years and 978 (45·5%) were men. SARS-CoV-2 seroprevalence was 19·0% (95% CI 15·1-23·5%) in 2020 and 53·0% (95% CI 49·6-56·4) in 2021. The prevalence ratio was 2·47 (95% CI 1·94-3·15) comparing 2020 with 2021 after adjusting for age, sex, and community. Almost half of all participants who tested positive reported no symptoms in the preceding six months. INTERPRETATION: Following the second wave, one in two people had been infected with SARS-CoV-2 suggesting high levels of community transmission. Our results suggest that 184,800 (172,900-196,700) SARS-CoV-2 infections occurred in these three communities alone, greatly exceeding the reported number of cases for the whole city. Further seroprevalence surveys are needed to understand transmission during the current third wave despite high prevalence of past infections. FUNDING: GCRF, Government of Canada, Wellcome Trust, Bavarian State Ministry of Sciences, Research, and the Arts

Protective immune trajectories in early viral containment of non-pneumonic SARS-CoV-2 infection

The antiviral immune response to SARS-CoV-2 infection can limit viral spread and prevent development of pneumonic COVID-19. However, the protective immunological response associated with successful viral containment in the upper airways remains unclear. Here, we combine a multi-omics approach with longitudinal sampling to reveal temporally resolved protective immune signatures in non-pneumonic and ambulatory SARS-CoV-2 infected patients and associate specific immune trajectories with upper airway viral containment. We see a distinct systemic rather than local immune state associated with viral containment, characterized by interferon stimulated gene (ISG) upregulation across circulating immune cell subsets in non-pneumonic SARS-CoV2 infection. We report reduced cytotoxic potential of Natural Killer (NK) and T cells, and an immune-modulatory monocyte phenotype associated with protective immunity in COVID-19. Together, we show protective immune trajectories in SARS-CoV2 infection, which have important implications for patient prognosis and the development of immunomodulatory therapies

Nucleocapsid-specific T cell responses associate with control of SARS-CoV-2 in the upper airways before seroconversion

Despite intensive research since the emergence of SARS-CoV-2, it has remained unclear precisely which components of the early immune response protect against the development of severe COVID-19. Here, we perform a comprehensive immunogenetic and virologic analysis of nasopharyngeal and peripheral blood samples obtained during the acute phase of infection with SARS-CoV-2. We find that soluble and transcriptional markers of systemic inflammation peak during the first week after symptom onset and correlate directly with upper airways viral loads (UA-VLs), whereas the contemporaneous frequencies of circulating viral nucleocapsid (NC)-specific CD4+ and CD8+ T cells correlate inversely with various inflammatory markers and UA-VLs. In addition, we show that high frequencies of activated CD4+ and CD8+ T cells are present in acutely infected nasopharyngeal tissue, many of which express genes encoding various effector molecules, such as cytotoxic proteins and IFN-γ. The presence of IFNG mRNA-expressing CD4+ and CD8+ T cells in the infected epithelium is further linked with common patterns of gene expression among virus-susceptible target cells and better local control of SARS-CoV-2. Collectively, these results identify an immune correlate of protection against SARS-CoV-2, which could inform the development of more effective vaccines to combat the acute and chronic illnesses attributable to COVID-19

Enhanced Spike-specific, but attenuated Nucleocapsid-specific T cell responses upon SARS-CoV-2 breakthrough versus non-breakthrough infections

SARS-CoV-2 vaccine breakthrough infections frequently occurred even before the emergence of Omicron variants. Yet, relatively little is known about the impact of vaccination on SARS-CoV-2-specific T cell and antibody response dynamics upon breakthrough infection. We have therefore studied the dynamics of CD4 and CD8 T cells targeting the vaccine-encoded Spike and the non-encoded Nucleocapsid antigens during breakthrough infections (BTI, n=24) and in unvaccinated control infections (non-BTI, n=30). Subjects with vaccine breakthrough infection had significantly higher CD4 and CD8 T cell responses targeting the vaccine-encoded Spike during the first and third/fourth week after PCR diagnosis compared to non-vaccinated controls, respectively. In contrast, CD4 T cells targeting the non-vaccine encoded Nucleocapsid antigen were of significantly lower magnitude in BTI as compared to non-BTI. Hence, previous vaccination was linked to enhanced T cell responses targeting the vaccine-encoded Spike antigen, while responses against the non-vaccine encoded Nucleocapsid antigen were significantly attenuated

Molecular analysis of the mechanisms involved in THBS4 differential geneexpression in the human brain

Durante las últimas décadas ha crecido el interés en cuestiones como qué nos hace humanos o cómo difiere a nivel molecular el cerebro humano del de nuestros parientes más cercanos. Se han podido identificar cientos de genes con diferencias de expresión entre el ser humano y otros primates no humanos. Sin embargo, es importante estudiar más en detalle estos genes para comprobar si realmente están involucrados en las características específicas de nuestro cerebro. Las trombospondinas son glicoproteínas extracelulares multiméricas que modulan las interacciones entre células y con la matriz extracelular y que se han implicado en la sinaptogénesis. Dentro de la familia de las trombospondinas, los genes de la trombospondina-2 (THBS2) y trombospondina-4 (THBS4) se expresan, respectivamente, alrededor de 2 y 6 veces más en la corteza cerebral humana en comparación con la de chimpancés o macacos. Para conocer las causas de estas diferencias de expresión, hemos llevado a cabo un análisis comparativo y funcional de la región promotora de THBS4 en humanos y en chimpancés. Hemos identificado y validado un sitio de inicio de transcripción (TSS) alternativo para THBS4 que se encuentra 44 kb aguas arriba del TSS de referencia y que genera una nueva isoforma de ARNm que podría haber aparecido más tarde durante la evolución. Para comparar los niveles de expresión de ambos transcritos se realizó RT-PCR cuantitativa en diferentes tejidos humanos y en muestras de corteza cerebral de 11 humanos, 11 chimpancés y 8 macacos. Curiosamente, la nueva isoforma de THBS4 se expresa principalmente en los tejidos cerebrales. Por otra parte, la diferencia de expresión entre humanos y primates no humanos para la isoforma alternativa son consistentes con la encontrada al analizar la expresión total de THBS4. Por tanto, el aumento de la expresión de THBS4 en el cerebro humano parece estar relacionado con una mayor transcripción a partir del promotor alternativo. Para evaluar la actividad de ambas secuencias promotoras en humanos y en chimpancés, hemos llevado a cabo ensayos con un gen indicador en diferentes líneas celulares humanas. Se han encontrado diferencias significativas entre los dos promotores, aunque en las líneas de neuroblastoma que utilizamos no existen diferencias significativas entre especies. Este resultado es consistente con la búsqueda de sitios de unión de factores de transcripción en la región del promotor alternativo, ya que sólo se detectaron tres posibles sitios de unión diferentes entre ambas especies. Se ha comparado también la metilación del ADN en una isla CpG situada aguas arriba de la nueva isoforma de THBS4 en 5 humanos y en 5 chimpancés, detectando niveles bajos de metilación en ambas especies. Basándonos en las predicciones informáticas disponibles y en experimentos piloto de ChIP-Seq, hemos buscado posibles enhancers que estén controlando el promotor alternativo de THBS4, pero no hemos encontrado ningún candidato fiable. Por último, en humanos, se ha visto que hay dos haplotipos de THBS4 diferentes que se encuentran mantenidos mediante selección equilibradora. Sin embargo, la comparación experimental de ambos no muestra ningún efecto del genotipo sobre la expresión de THBS4. Aunque no se ha conseguido identificar la causa concreta del incremento en los niveles de THBS4 en humanos, en base a nuestros resultados sugerimos que la expresión diferencial del gen podría estar relacionada con una secuencia potenciadora específica del cerebro que no hemos conseguido localizar. Comprender como se encuentra regulada esta posible secuencia potenciadora podría ser relevante para entender cuales son las consecuencias funcionales de las diferencias de expresión de THBS4 sobre la evolución del cerebro y, en última instancia, darnos pistas sobre como nos convertimos en humanos.The last decades have seen a growing interest in what makes us humans and how the human brain differs from that of our closest relatives at the molecular level. Hundreds of genes with expression differences between human and non-human primates have been identified. However, it is important to study these genes in more detail to see if they are really involved in human brain characteristics. Thrombospondins are multimeric extracellular glycoproteins that modulate cell-cell and extracellular matrix interactions and have been implicated in synaptogenesis. Within the thrombospondin family, thrombospondin-2 (THBS2) and thrombospondin-4 (THBS4) show, respectively, a ~2-fold and ~6-fold upregulation in human cerebral cortex compared to chimpanzees and macaques. To analyze the causes of these expression differences, we have carried out a comparative and functional analysis of the THBS4 promoter region in humans and chimpanzees. We have identified and validated an alternative transcription start site (TSS) for THBS4 that is located ~44 kb upstream from the known TSS and generates a new mRNA isoform that might have appeared later that the reference one during evolution. To compare expression levels of both mRNAs, we performed quantitative RT-PCR in different human tissues and cortical regions of 11 humans, 11 chimpanzees and 8 macaques. Interestingly, the new isoform of THBS4 is expressed mainly in brain tissues. Moreover, expression differences between human and non-human primate cortex for this alternative isoform are consistent with those shown for total THBS4 expression. Increased THBS4 expression in the human brain therefore appears to be related to higher transcription from the alternative promoter. To evaluate the activity of both THBS4 promoter sequences we performed reporter assays from humans and chimpanzees in different human cell lines. We have found significant differences between both promoters, but not between species, in the neuroblastoma cell lines assayed. This result is consistent with the search for transcription factor binding sites (TFBS) in the alternative promoter region, which only detected three putative TFBS differentially predicted between both species. We also compared the DNA methylation in a CpG island upstream the new isoform in 5 humans and 5 chimpanzees detecting similar low methylation levels in all of them. Based in the computational predictions available online and ChIP-Seq pilot experiments, we searched for a putative enhancer region controlling the THBS4 alternative promoter without finding any reliable candidate. Finally, in humans, THBS4 has been associated to two different haplotypes that are maintained by balancing selection, but experimental analysis did not show any effect of the genotype over THBS4 gene expression. Although we have not been able to identify the ultimate cause of the increased THBS4 levels in humans, based on all our results we suggest that the differential gene expression might be related to a brain-specific enhancer sequence that has so far escaped our scrutiny. Understanding its regulation could be relevant to the functional consequences of THBS4 expression differences during human brain evolution and ultimately could give us clues of how we became humans

Viaja con la mente

Este trabajo obtuvo la segunda mención especial de la modalidad B de los Premios Joaquín Sama 2006Se describe un concurso que consistía en realizar varias pruebas y que pretendía preparar a los alumnos para que tuvieran un comportamiento adecuado en el centro escolar. El objetivo principal del proyecto era mejorar la convivencia en el centro escolar, además de promover el trabajo en equipo, aumentar la motivación del alumnado, potenciar la búsqueda de soluciones alternativas ante los problemas diarios en el aula y el centro, dotar al alumno de los recursos necesarios para afrontar los conflictos de forma constructiva, etc. Se detalla la organización y el desarrollo del proyecto, su temporalización, la metodología seguida, los recursos necesarios para llevarlo a cabo, etc..ExtremaduraConsejería de Educación. Dirección General de Política Educativa; Calle Delgado Valencia, 6; 06800 Mérida (Badajoz); Tel. +34924006714; Fax +34924006716; [email protected]

From first to second wave: Follow-up of the prospective COVID-19 cohort (KoCo19) in Munich (Germany).

BACKGROUND: In the 2nd year of the COVID-19 pandemic, knowledge about the dynamics of the infection in the general population is still limited. Such information is essential for health planners, as many of those infected show no or only mild symptoms and thus, escape the surveillance system. We therefore aimed to describe the course of the pandemic in the Munich general population living in private households from April 2020 to January 2021. METHODS: The KoCo19 baseline study took place from April to June 2020 including 5313 participants (age 14 years and above). From November 2020 to January 2021, we could again measure SARS-CoV-2 antibody status in 4433 of the baseline participants (response 83%). Participants were offered a self-sampling kit to take a capillary blood sample (dry blood spot; DBS). Blood was analysed using the Elecsys® Anti-SARS-CoV-2 assay (Roche). Questionnaire information on socio-demographics and potential risk factors assessed at baseline was available for all participants. In addition, follow-up information on health-risk taking behaviour and number of personal contacts outside the household (N = 2768) as well as leisure time activities (N = 1263) were collected in summer 2020. RESULTS: Weighted and adjusted (for specificity and sensitivity) SARS-CoV-2 sero-prevalence at follow-up was 3.6% (95% CI 2.9-4.3%) as compared to 1.8% (95% CI 1.3-3.4%) at baseline. 91% of those tested positive at baseline were also antibody-positive at follow-up. While sero-prevalence increased from early November 2020 to January 2021, no indication of geospatial clustering across the city of Munich was found, although cases clustered within households. Taking baseline result and time to follow-up into account, men and participants in the age group 20-34 years were at the highest risk of sero-positivity. In the sensitivity analyses, differences in health-risk taking behaviour, number of personal contacts and leisure time activities partly explained these differences. CONCLUSION: The number of citizens in Munich with SARS-CoV-2 antibodies was still below 5% during the 2nd wave of the pandemic. Antibodies remained present in the majority of SARS-CoV-2 sero-positive baseline participants. Besides age and sex, potentially confounded by differences in behaviour, no major risk factors could be identified. Non-pharmaceutical public health measures are thus still important

The genome sequencing of an albino Western lowland gorilla reveals inbreeding in the wild

Altres ajuts: ERC grant: ERC-2010-StG_20091118. The Andalusian Government for grants CSD2007-00008 and CVI-3488, supported by FEDER to JLG-S The Barcelona Zoo (Ajuntament de Barcelona) for an award to JP-M. EEE is an investigator with the Howard Hughes Medical InstituteBackground: the only known albino gorilla, named Snowflake, was a male wild born individual from Equatorial Guinea who lived at the Barcelona Zoo for almost 40 years. He was diagnosed with non-syndromic oculocutaneous albinism, i.e. white hair, light eyes, pink skin, photophobia and reduced visual acuity. Despite previous efforts to explain the genetic cause, this is still unknown. Here, we study the genetic cause of his albinism and making use of whole genome sequencing data we find a higher inbreeding coefficient compared to other gorillas.- Results: we successfully identified the causal genetic variant for Snowflake's albinism, a non-synonymous single nucleotide variant located in a transmembrane region of SLC45A2. This transporter is known to be involved in oculocutaneous albinism type 4 (OCA4) in humans. We provide experimental evidence that shows that this amino acid replacement alters the membrane spanning capability of this transmembrane region. Finally, we provide a comprehensive study of genome-wide patterns of autozygogosity revealing that Snowflake's parents were related, being this the first report of inbreeding in a wild born Western lowland gorilla.- Conclusions: in this study we demonstrate how the use of whole genome sequencing can be extended to link genotype and phenotype in non-model organisms and it can be a powerful tool in conservation genetics (e.g., inbreeding and genetic diversity) with the expected decrease in sequencing cos

Determinants of anti-S immune response at 6 months after COVID-19 vaccination in a multicentric European cohort of healthcare workers - ORCHESTRA project

BackgroundThe duration of immune response to COVID-19 vaccination is of major interest. Our aim was to analyze the determinants of anti-SARS-CoV-2 IgG titer at 6 months after 2-dose vaccination in an international cohort of vaccinated healthcare workers (HCWs). MethodsWe analyzed data on levels of anti-SARS-CoV-2 Spike antibodies and sociodemographic and clinical characteristics of 6,327 vaccinated HCWs from 8 centers from Germany, Italy, Romania and Slovakia. Time between 1(st) dose and serology ranged 150-210 days. Serological levels were log-transformed to account for the skewness of the distribution and normalized by dividing them by center-specific standard errors, obtaining standardized values. We fitted center-specific multivariate regression models to estimate the cohort-specific relative risks (RR) of an increase of 1 standard deviation of log antibody level and corresponding 95% confidence interval (CI), and finally combined them in random-effects meta-analyses. ResultsA 6-month serological response was detected in 99.6% of HCWs. Female sex (RR 1.10, 95%CI 1.00-1.21), past infection (RR 2.26, 95%CI 1.73-2.95) and two vaccine doses (RR 1.50, 95%CI 1.22-1.84) predicted higher IgG titer, contrary to interval since last dose (RR for 10-day increase 0.94, 95%CI 0.91-0.97) and age (RR for 10-year increase 0.87, 95%CI 0.83-0.92). M-RNA-based vaccines (p<0.001) and heterologous vaccination (RR 2.46, 95%CI 1.87-3.24, one cohort) were associated with increased antibody levels. ConclusionsFemale gender, young age, past infection, two vaccine doses, and m-RNA and heterologous vaccination predicted higher antibody level at 6 months. These results corroborate previous findings and offer valuable data for comparison with trends observed with longer follow-ups